Canada - TSX-V:SGMD - CA79549X1096 - Common Stock
The current stock price of SGMD.CA is 0.21 CAD. In the past month the price increased by 20%. In the past year, price decreased by -40%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| PRN.CA | PROFOUND MEDICAL CORP | N/A | 283.73M | ||
| MIR.CA | MEDMIRA INC | N/A | 53.08M | ||
| TLT.CA | THERALASE TECHNOLOGIES INC | N/A | 52.03M | ||
| CNVI.CA | CONAVI MEDICAL CORP | N/A | 42.98M | ||
| ASG.CA | AURORA SPINE CORP | N/A | 23.17M | ||
| PINK.CA | PERIMETER MEDICAL IMAGING AI | N/A | 22.57M | ||
| NSCI.CA | NANALYSIS SCIENTIFIC CORP | N/A | 21.82M | ||
| MDX.CA | MEDX HEALTH CORP | N/A | 16.99M | ||
| VPT.CA | VENTRIPOINT DIAGNOSTICS LTD | N/A | 16.77M | ||
| THRM.CA | THERMA BRIGHT INC | N/A | 4.54M | ||
| VVTM.CA | VVT MED INC | N/A | 20.05M |
Salona Global Medical Device Corp. engages in the provision of financial and consultancy services to the mental health and addiction industry. The company is headquartered in Carlsbad, California and currently employs 144 full-time employees. The company went IPO on 2014-03-28. Through strategic acquisitions, it leverages the intellectual properties of specialized companies to deliver products and services through its subsidiaries. The company develops, manufactures, and sells medical devices, some of which are proprietary and white labels. Its products include devices used for pain management and physical therapy treatments, including cold/hot therapy products, neuromuscular electrical stimulation devices, transcutaneous electrical nerve stimulation devices, ultrasound treatment devices, as well as wearable technology and other products used for prevention, treatment, and rehabilitation of the human body. Its operations are focused predominantly on the business of recovery science, technologies that help individuals recover from surgery and prevent disease. Its subsidiaries consist of South Dakota Partners, Inc., Simbex, LLC, ALG Health Plus, LLC and others.
SALONA GLOBAL MEDICAL DEVICE
6160 Innovation Way
Carlsbad CALIFORNIA US
CEO: Jaime Gerber
Employees: 144
Phone: 18007606826
Salona Global Medical Device Corp. engages in the provision of financial and consultancy services to the mental health and addiction industry. The company is headquartered in Carlsbad, California and currently employs 144 full-time employees. The company went IPO on 2014-03-28. Through strategic acquisitions, it leverages the intellectual properties of specialized companies to deliver products and services through its subsidiaries. The company develops, manufactures, and sells medical devices, some of which are proprietary and white labels. Its products include devices used for pain management and physical therapy treatments, including cold/hot therapy products, neuromuscular electrical stimulation devices, transcutaneous electrical nerve stimulation devices, ultrasound treatment devices, as well as wearable technology and other products used for prevention, treatment, and rehabilitation of the human body. Its operations are focused predominantly on the business of recovery science, technologies that help individuals recover from surgery and prevent disease. Its subsidiaries consist of South Dakota Partners, Inc., Simbex, LLC, ALG Health Plus, LLC and others.
The current stock price of SGMD.CA is 0.21 CAD. The price decreased by -2.33% in the last trading session.
SGMD.CA does not pay a dividend.
SGMD.CA has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
SGMD.CA stock is listed on the TSX Venture Exchange exchange.
SALONA GLOBAL MEDICAL DEVICE (SGMD.CA) has a market capitalization of 11.97M CAD. This makes SGMD.CA a Nano Cap stock.
You can find the ownership structure of SALONA GLOBAL MEDICAL DEVICE (SGMD.CA) on the Ownership tab.
ChartMill assigns a technical rating of 1 / 10 to SGMD.CA. When comparing the yearly performance of all stocks, SGMD.CA is a bad performer in the overall market: 75.48% of all stocks are doing better.
ChartMill assigns a fundamental rating of 2 / 10 to SGMD.CA. Both the profitability and financial health of SGMD.CA have multiple concerns.
Over the last trailing twelve months SGMD.CA reported a non-GAAP Earnings per Share(EPS) of -0.3. The EPS decreased by -3.07% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -23.11% | ||
| ROE | -80.88% | ||
| Debt/Equity | 0.83 |
5 analysts have analysed SGMD.CA and the average price target is 1.17 CAD. This implies a price increase of 458.57% is expected in the next year compared to the current price of 0.21.
For the next year, analysts expect an EPS growth of -50% and a revenue growth 83.45% for SGMD.CA